NCT04578847 A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) Status UNKNOWN Phase PHASE2
NCT04530565 Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04439305 Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) Status WITHDRAWN Phase PHASE2
NCT04329325 Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04313634 Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans Status COMPLETED Phase PHASE2
NCT04164069 Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Status COMPLETED Phase PHASE1
NCT04155411 Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP Status UNKNOWN Phase PHASE4
NCT04147533 Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03906292 Frontline Asciminib Combination in Chronic Phase CML Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03885830 Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients Status COMPLETED Phase N/A
NCT03878524 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Status TERMINATED Phase PHASE1
NCT03844360 Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease Status RECRUITING Phase PHASE4
NCT03654768 Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03625388 Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Status COMPLETED Phase PHASE2
NCT03595917 ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Status RECRUITING Phase PHASE1
NCT03573596 Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment Status UNKNOWN Phase PHASE2
NCT03564470 Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL Status UNKNOWN Phase PHASE2/PHASE3
NCT03560908 Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation Status WITHDRAWN Phase PHASE1
NCT03516279 Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Status ACTIVE_NOT_RECRUITING Phase PHASE2